ONPEPS has not identified a published case series, FDA warning letter, or health-department alert tying a specific harm to research-labelled CJC-1295 or ipamorelin, and we say so rather than implying one. What has been documented is the product problem.
Contents that do not match labels
Anti-doping laboratories analysing black-market growth-promoting products have repeatedly found contents that do not match the label. A 2018 study documented this. This means the vial you buy may contain a completely different substance, or a dose that differs significantly from the label.
Forged COAs
On July 30, 2026, the founder of Paradigm Peptides — a US research-chemical vendor with roughly 54,000 customers — was sentenced to 70 months in federal prison after admitting he forged the lab certificates his customers relied on. His products were adulterated SARMs rather than peptides, but the certificate problem is the same across the market, which is why the vendor boards exist.
The June 2026 warning letter
On June 17, 2026, the FDA sent a warning letter to a supplier called Wholesale Peptide for selling injectable peptides as unapproved drugs. The FDA ruled that once a product page describes what the peptide does in the body, the “for research use only” label is irrelevant.
What this means for CJC-1295 and Ipamorelin
Neither compound is approved, and neither can be lawfully compounded. Products sold on the market come from unregulated suppliers, and purity, contamination, and dosing accuracy cannot be reliably guaranteed. Choosing reputable channels and requesting third-party testing reports is a basic risk-reduction step.
Conclusion
The compounds’ own side effects are mostly mild. The serious problem is the product itself — what you are actually injecting, and whether it matches the label.